EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Amino Acid Stress Response Genes Contribute to a 25‐Fold Increased Risk of L‐Asparaginase–Induced Hypersensitivity

Spencer J Anderson iD, Erika N Scott, Edward J Raack, Wan-Chun Chang iD, Miguel Córdova-Delgado iD, Jessica N Trueman, Catrina M Loucks, S Rod Rassekh, Colin J D Ross, Bruce C Carleton, Canadian Pharmacogenomics Network for Drug Safety (CPNDS) consortium

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31668 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Spencer J Anderson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Asparaginase, Drug Hypersensitivity, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Amino Acids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Genome Canada, Genome British Columbia, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

L‐asparaginase is essential in treating pediatric acute lymphoblastic leukemia (ALL) but is limited by hypersensitivity reactions in up to 70% of patients, leading to severe, dose‐limiting complications and compromised event‐free survival. Procedure This study conducted a genome‐wide association study (GWAS) in a discovery cohort of 221 pediatric cancer patients who experienced l‐asparaginase–induced hypersensitivity reactions (≥CTCAE grade 2) and 705 controls without hypersensitivity despite equivalent exposure. Results were replicated in an independent cohort of 41 cases and 139 controls.

Results

Significant associations were identified between hypersensitivity and four genes crucial for amino acid stress response: CYP1B1 (rs59569490; odds ratio [OR] = 8.5; 95% confidence interval [CI], 3.9–18.5; p = 1.5 × 10 −10 ), SEC16B (rs115461320; OR = 4.2; 95% CI, 2.5–7.9; p = 1.2 × 10 −6 ), OPLAH (rs11993268; OR = 4.8; 95% CI, 2.4–9.9; p = 2.0 × 10 −6 ), and SORCS2 (rs11940340; OR = 6.7; 95% CI, 2.8–15.7; p = 5.7 × 10 −7 ). Variants in SEC16B , OPLAH , and SORCS2 remained significant in the analysis of the replication cohort ( p < 0.05). Patients who carried risk alleles in two or more of these genes experienced an 86.4% increased incidence of hypersensitivity reactions in the discovery cohort (OR = 25.2; 95% CI, 7.4–86.2; p = 1.0 × 10 −10 ), which was replicated in the independent cohort with a 100% incidence in carriers ( p = 0.04).

Conclusions

The cumulative incidence of these large effect variants highlights their significance for the identification of patients at high risk of l‐asparaginase–induced hypersensitivity. Successfully identifying patients at increased risk of hypersensitivity reactions can inform personalized treatment strategies and limit these harmful dose‐limiting reactions in pediatric ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsparaginaseDrug HypersensitivityPrecursor Cell Lymphoblastic Leukemia-LymphomaAmino AcidsAntineoplastic AgentsHumansChildFemaleMaleGenome-Wide Association StudyChild, PreschoolAdolescentCase-Control StudiesInfantPolymorphism, Single NucleotideFollow-Up StudiesCytochrome P-450 CYP1B1

Stichwörter der Autor:innen

acute lymphoblastic leukemiahypersensitivityl‐asparaginasepediatrics

Substanzen

AsparaginaseAmino AcidsAntineoplastic AgentsCYP1B1 protein, humanCytochrome P-450 CYP1B1

Autor:innen und Institutionen

  • Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
  • BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
  • Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
  • Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, Canada.
  • Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
  • Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.

ORCID-Profile: Spencer J Anderson, Wan-Chun Chang, Miguel Córdova-Delgado

Förderung

  • Genome Canada
  • Genome British Columbia
  • CIHR
  • Provincial Health Services Authority
  • BC Children's Hospital Foundation
  • Health Canada
  • Canadian Institutes of Health Research

Zitieren

APA

Anderson, S. J., Scott, E. N., Raack, E. J., Chang, W. C., Córdova-Delgado, M., Trueman, J. N., Loucks, C. M., Rassekh, S. R., Ross, C. J. D., Carleton, B. C., & Canadian Pharmacogenomics Network for Drug Safety (CPNDS) consortium (2025). Amino Acid Stress Response Genes Contribute to a 25‐Fold Increased Risk of L‐Asparaginase–Induced Hypersensitivity. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31668

Vancouver

Anderson SJ, Scott EN, Raack EJ, Chang WC, Córdova-Delgado M, Trueman JN, et al. Amino Acid Stress Response Genes Contribute to a 25‐Fold Increased Risk of L‐Asparaginase–Induced Hypersensitivity. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31668

BibTeX
@article{Anderson2025,
  author = {Anderson, Spencer J and Scott, Erika N and Raack, Edward J and Chang, Wan-Chun and Córdova-Delgado, Miguel and Trueman, Jessica N and Loucks, Catrina M and Rassekh, S Rod and Ross, Colin J D and Carleton, Bruce C and Canadian Pharmacogenomics Network for Drug Safety (CPNDS) consortium, Canadian Pharmacogenomics Network for Drug Safety (CPNDS) consortium},
  title = {Amino Acid Stress Response Genes Contribute to a 25‐Fold Increased Risk of L‐Asparaginase–Induced Hypersensitivity},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31668}
}
Kostenlos starten →